Powerful new weight-loss drugs promised a health reset for millions—yet emerging evidence suggests many of those gains can slip away surprisingly fast once the injections stop. And this is the part most people miss: the real story might not be about losing weight, but about what happens when the medication ends.
A recent analysis of people taking the weight-loss medication Mounjaro (the drug name is tirzepatide, made by Eli Lilly) found that many of the health benefits faded within a year after stopping the drug, especially in those who regained more weight. In other words, the more weight people put back on, the more their improvements in waist size, blood pressure, cholesterol, blood sugar, and insulin resistance tended to reverse. That raises a big, and somewhat uncomfortable, question: are these medications essentially lifelong treatments for many people?
Researchers looked at data from the SURMOUNT-4 clinical trial, which included 308 adults who first took tirzepatide for 36 weeks. During this initial period, participants lost weight and saw their cardiometabolic health markers—things like waist circumference, blood pressure, cholesterol profiles, and measures of blood sugar control—move in a healthier direction. After those 36 weeks, people were randomly assigned either to keep taking tirzepatide or to switch to a placebo for another 52 weeks, allowing researchers to see what would happen once the active drug was withdrawn.
To understand weight regain, the team evaluated participants at week 88, the final week of the study. They calculated how much of the weight lost between week 0 and week 36 had come back by that point, then grouped people into four categories: less than 25% of lost weight regained, 25% to less than 50%, 50% to less than 75%, and 75% or more. This kind of categorization helps show not just whether people regain weight, but how strongly the amount of regain is tied to changes in other health measures.
Here’s where it gets controversial: after stopping tirzepatide, 82% of participants regained at least 25% of their original weight loss within one year. Those who regained more weight tended to see bigger increases in waist circumference and a greater undoing of earlier improvements in blood pressure, blood fats, and blood sugar markers. That pattern suggests that, for many people, the health benefits of these drugs might be tightly linked to staying on treatment—or at least to maintaining the weight loss through some other means.
For participants who regained less than 25% of the weight they had lost, the changes were relatively modest. On average, their waist circumference grew by 0.8 cm, systolic blood pressure rose by 6.8 mmHg, HbA1c (a long-term blood sugar marker) increased by 0.14%, and fasting insulin changed by about -4.0%. While these shifts are not trivial, they are considerably smaller than the changes seen in people who regained more weight, highlighting how even partial maintenance of weight loss can help preserve some health benefits.
But as weight regain climbed, the cardiometabolic picture worsened. Among those who regained 50% to less than 75% of their lost weight, average waist circumference increased by 10.1 cm. Their systolic blood pressure rose by 9.6 mmHg, non-HDL (the “bad” fraction of cholesterol that excludes HDL) went up by 8.4%, HbA1c increased by 0.27%, and fasting insulin jumped by 46.2%. These numbers reflect a substantial erosion of the earlier gains and hint at the body’s powerful tendency to revert toward its previous metabolic state when weight returns.
At the highest level of weight regain—75% or more of lost weight regained—these trends became even more pronounced. On average, waist circumference increased by 14.7 cm, systolic blood pressure rose by 10.4 mmHg, non-HDL cholesterol climbed by 10.8%, HbA1c went up by 0.35%, and fasting insulin increased by 26.3%. Taken together, these changes show that for people who regain most of the weight, much of the initial cardiometabolic improvement is essentially reversed, which may put them closer to where they started in terms of health risk.
The study authors concluded that, in this post-hoc analysis of the SURMOUNT-4 trial, most participants with obesity who had achieved weight loss during 36 weeks of tirzepatide treatment regained at least 25% of that weight within a year of stopping. They also emphasized that greater weight regain was linked to a stronger reversal of the initial cardiometabolic improvements, compared with those who managed to sustain more of their weight loss. From their perspective, this reinforces an important and sometimes uncomfortable reality: for many people, obesity behaves like a long-term medical condition that may require ongoing treatment.
That leads directly into one of the boldest and most debated ideas in this space: should obesity be treated like other chronic diseases that usually require long-term or even lifelong therapy? A spokesperson for Eli Lilly responded to the findings by stressing that obesity is a chronic, progressive disease that often needs long-term management. They argued that, just like with conditions such as high blood pressure or diabetes, treatment should continue when medically appropriate to maintain benefits, rather than being seen as a short-term fix.
The company representative also pointed out that lifestyle changes alone—such as diet, physical activity, and counseling—may not be enough to produce lasting, clinically meaningful weight loss for everyone. Many people, they suggested, need different levels of medical support combined with personalized lifestyle strategies in order to successfully lose weight and keep it off over the long term. This perspective can be controversial because it challenges the common belief that willpower and lifestyle are always sufficient, and instead frames obesity as a complex disease influenced by biology, environment, and behavior.
Referring back to their analysis of SURMOUNT-4, the spokesperson highlighted that about 82.5% of participants who stopped tirzepatide regained at least a quarter of the weight they had lost within a year. They noted that this pattern aligns with findings from other studies cited in the paper, suggesting that significant weight regain after stopping treatment may be common, not an outlier. According to their interpretation, the associated reversal of improvements in blood pressure, cholesterol, blood glucose, and insulin sensitivity supports the case for continued treatment in adults living with obesity, especially when the medication is well tolerated and clinically indicated.
But here’s where the discussion widens: not all weight-loss or metabolic drugs have the same effects across different conditions. On the same day, new information from phase III of Novo Nordisk’s EVOKE trial was shared. In this study, researchers investigated whether semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, could slow cognitive decline in people with Alzheimer’s disease. Despite earlier hopes that GLP-1 drugs might offer neuroprotective benefits, the trial found that semaglutide did not have an effect on the progression of cognitive decline in this population.
This contrast is striking. On one hand, drugs like tirzepatide and semaglutide can have powerful effects on weight and cardiometabolic health markers. On the other hand, at least in the EVOKE trial, semaglutide did not deliver the hoped-for benefits in slowing Alzheimer’s-related cognitive decline. That raises important questions about how broadly these medications should be expected to work beyond weight and metabolic health, and whether the excitement around them sometimes outpaces what the evidence actually shows for other conditions.
So, what does all of this mean for everyday people considering or already using drugs like Mounjaro? One possible interpretation—likely to spark debate—is that these medications might need to be viewed less as short-term weight-loss tools and more as long-term disease-management therapies, similar to blood pressure or cholesterol drugs. But that viewpoint raises tough practical and ethical questions: Is it realistic or fair to expect people to remain on expensive medications for years? How should health systems and insurers respond? And what happens to people who cannot access or afford these treatments but still struggle with obesity?
Now, over to you: Do you think it is reasonable to treat obesity with long-term medication in the same way we treat high blood pressure or diabetes, or does that approach risk medicalizing something you feel should be handled primarily through lifestyle and personal responsibility? Should patients be clearly told upfront that stopping drugs like Mounjaro may mean regaining weight and losing health benefits, even after months of progress? Share your thoughts—do these findings make you feel more confident in these medications, more cautious, or somewhere in between?
